Skip to main content
LFSTLifeStance Health Group, Inc.Sell5.0·$11.27-1.40%
SellModerate Confidence
Investment thesis

LifeStance is generating 21% year-over-year revenue growth and converting earnings to free cash flow at an exceptional multiple of reported income, but the stock has risen to within 6.9% of its take-profit level with a reward-to-risk ratio barely above 1-to-1, leaving insufficient asymmetry to justify new entry at current prices.

Thesis pillars

  • Sector Leading Revenue GrowthStable
  • Exceptional Free Cash Flow ConversionStable
  • Inadequate Entry GeometryStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

LifeStance Health Group, Inc. (LFST) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Care Facilities

Sell if holding. Analyst target reached at $11.27 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (3.0% away).

LifeStance Health Group operates one of the nation's largest outpatient mental health platforms, employing 8,040 licensed clinicians across 572 centers in 33 states, offering psychiatric evaluations, therapy and psychological testing via in-person and virtual visits. Revenue is... Read more

$11.27+1.1% A.UpsideScore 5.0/10#27 of 36 Medical Care Facilities
QualityF-score8 / 9FCF yield3.27%
Stop $10.48Target $11.39(resistance)A.R:R -1.2:1
Analyst target$10.55-6.4%10 analysts
$11.39our TP
$11.27price
$10.55mean
$9
$13

Sell if holding. Analyst target reached at $11.27 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (3.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.

Passes 5/8 gates (positive momentum, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.

10-K grounded · weekly refresh

About LifeStance Health Group, Inc.

About LifeStance Health Group, Inc.

LifeStance Health Group employed 8,040 licensed mental health clinicians across 572 centers in 33 states as of December 31, 2025, making it one of the nation's largest outpatient mental health platforms by clinician count and geographic scale. The platform delivered approximately 9.0 million patient visits to more than 1.0 million unique patients in 2025. Revenue is primarily generated through fee-for-service arrangements with commercial in-network payors, which accounted for 90% of total revenue in 2025, with government payors and self-pay contributing 5% and 4%, respectively.

LifeStance earns revenue on a per-visit basis when patients receive care from employed clinicians, either in-person at one of its 572 centers or through the company's virtual care platform. Commercial in-network payors supply 90% of revenue, with UnitedHealthcare and Elevance Health each individually exceeding 10% — comprising 14% and 15% of total revenue in 2025, respectively. Contracts with payors are typically structured as fee-for-service arrangements with negotiated reimbursement rates. Clinicians are employed as W-2 employees rather than independent contractors, a model the company believes strengthens retention but requires ongoing investment in compensation and benefit packages. The company competes with other outpatient mental health providers, hospitals, digital health platforms and major retailers that have recently begun to offer mental healthcare services in certain markets.

Show full overview

Reimbursement risk from the two largest payors is material and named. Elevance Health and UnitedHealthcare together accounted for 29% of 2025 total revenue (14% and 15% per the 10-K disclosure), and the filing states that changes in their reimbursement rates or loss of in-network status may adversely impact results more than changes implemented by other payors. Separately, 5% of revenue comes from government payors subject to statutory rate-setting; the filing cites uncertainty around the One Big Beautiful Bill Act and its potential impact on Medicare and Medicaid funding, which could reduce or delay government program reimbursement.

See also: Healthcare · Medical Care Facilities

From LifeStance Health Group, Inc.'s most recent 10-K filing, extracted June 11, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-05
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202634d to earnings· next earnings call

Thesis

Rewards
Strong growth profile
Positive momentum
Risks
Analyst target reached - limited upside remaining
Near 52-week high (3.0% away)
Overbought (RSI 91)

Key Metrics

P/E (TTM)187.8
P/E (Fwd)28.7
Mkt Cap$4.3B
EV/EBITDA46.4
Profit Mgn1.6%
ROE1.6%
Rev Growth21.2%
Beta1.12
DividendNone
Rating analysts17

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.81neutral
IV64%elevated
Max Pain$11-2.4% vs spot

Concentration Risks(10-K Item 1A)

  • LOWCustomerElevance Health15%
    10-K Item 1A: 'UnitedHealthcare and Elevance Health, Inc., comprising 14% and 15% of our total revenue, respectively'
  • LOWCustomerUnitedHealthcare14%
    10-K Item 1A: 'UnitedHealthcare and Elevance Health, Inc., comprising 14% and 15% of our total revenue, respectively'

Material Events(8-K, last 90d)

  • 2026-03-11Item 5.02LOW
    Lisa Miller, age 52, promoted to COO and Principal Operating Officer effective March 10, 2026. Previously served as EVP, Practice Operations since February 2024. Annual base salary $485,000. No departure of prior incumbent cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.1
Quality Rank
2.6
Growth Rank
8.0
GatesA.R:R -1.2=NEGATIVEINSIDER 6.55%=EXTREMEExecutive change: officer departure/appointmentMomentum 7.5>=5.5NEWS EVENTS NONE RECENTEARNINGS PROXIMITY 34d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
91 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $7.29Resistance $11.62

Price Targets

$10
$11
A.Upside+1.1%
A.R:R-1.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-18.6% upside)
! Negative risk/reward — downside exceeds upside
! Insider activity: 6.55%=extreme

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-06 (34d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is LFST stock a buy right now?

Sell if holding. Analyst target reached at $11.27 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (3.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.48. Score 5.0/10, moderate confidence.

What is the LFST stock price target?

Take-profit target: $11.39 (+1.1% upside). Prior stop was $10.48. Stop-loss: $10.48.

What are the risks of investing in LFST?

Analyst target reached - limited upside remaining; Near 52-week high (3.0% away); Overbought (RSI 91).

Is LFST overvalued or undervalued?

LifeStance Health Group, Inc. trades at a P/E of 187.8 (forward 28.7). TrendMatrix value score: 4.6/10. Verdict: Sell.

What do analysts say about LFST?

17 analysts cover LFST with a consensus score of 4.1/5. Average price target: $11.

What does LifeStance Health Group, Inc. do?LifeStance Health Group operates one of the nation's largest outpatient mental health platforms, employing 8,040...

LifeStance Health Group operates one of the nation's largest outpatient mental health platforms, employing 8,040 licensed clinicians across 572 centers in 33 states, offering psychiatric evaluations, therapy and psychological testing via in-person and virtual visits. Revenue is generated on a per-visit basis; 90% came from commercial in-network payors in 2025, with clinicians treating more than 1.0 million unique patients through approximately 9.0 million visits.

Related stocks: NUTX (Nutex Health Inc.) · THC (Tenet Healthcare Corporation) · TOI (The Oncology Institute, Inc.) · UHS (Universal Health Services, Inc.) · SRTA (Strata Critical Medical, Inc.)
Home Stocks LFST

Latest news

Latest News

GlobeNewswire67d ago
The Motley Fool67d ago
HarianBasis.co67d ago
Yahoo Finance67d ago
Zacks Investment Research53d ago
Yahoo Finance53d agoEarnings
Yahoo Finance53d ago
Investing.com India60d agoEarnings
StockStory61d agoEarnings
Investing.com68d ago
TipRanks68d ago
StockStory68d ago
Simplywall.st68d ago
Investing.com54d ago
Yahoo Finance54d ago
Yahoo Finance66d ago
Investing.com52d ago
Investing.com52d ago
Stock Titan52d ago
Stock Titan52d ago
Loading more...